Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBT2 in prodromal or mild Alzheimer's disease
ACTRN12611001008910Phase 2Completed
- Sponsor
- Alterity Therapeutics
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing PBT2 with Placebo (2 arms). Primary endpoint: Brain amyloid burden. Started Mar 2012; status: completed.
02
Drugs
PBT2
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on ACTRN12611001008910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001008910.